A woman who had been living with three life-threatening autoimmune diseases for more than a decade has returned to a near-normal life after receiving a cell therapy designed to reset her immune system, scientists say.
The treatment was carried out last year at University Hospital Erlangen in Germany. According to the researchers, the case represents a world first.
The patient, who is 47, had already tried nine different treatments before the cell therapy was used. None had provided a lasting effect. At the time she received the treatment, her condition was severe enough that she needed daily blood transfusions and permanent blood-thinning medication to help control her illness.
The report describes the response to the therapy as remarkable, saying it reset the patient’s wayward immune system and allowed her to recover to a level close to normal life.
A severe, long-running illness
Autoimmune diseases occur when the immune system mistakenly attacks the body’s own tissues. In this case, the patient had three such conditions, and they had persisted for more than ten years. The source material does not specify the exact diagnoses, but it makes clear that the combined burden of the illnesses had been life-threatening and resistant to earlier treatment attempts.
Before the cell therapy, standard approaches had not been able to deliver lasting control. That left the patient dependent on supportive measures, including frequent transfusions and ongoing blood-thinning treatment.
A therapy aimed at resetting immunity
Cell therapy is being explored as a way to alter or reset dysfunctional immune activity in patients with severe autoimmune disease. In this case, the scientists involved say the intervention achieved an outcome that had not been seen before in a patient with this combination of conditions.
The account released by the researchers highlights the scale of the improvement after treatment. The woman, once in urgent need of intensive medical support, has now returned to a near-normal life.
The details provided are limited, but the case has drawn attention because of both the severity of the patient’s condition and the apparent durability of the response after years of unsuccessful treatment.
While the findings involve only one patient, the researchers describe the result as significant because it suggests a possible new route for treating severe autoimmune disease when conventional therapies fail.
The case was reported on 9 April 2026.
